Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

September 12, 2019 by Alan Khadavi

Palforzia (formerly AR101) and peanut allergy

Aimmune is seeking approval of its peanut allergy immunotherapy product, Palforzia.  We have extensively discussed AR101 a Potential Peanut Allergy Cure nearly a year ago, and the FDA is set to make a decision on it very soon.

Traditionally peanut allergies are managed by avoidance but the threat of accidental exposure cannot be nullified.  In the US, peanut allergy affects nearly 1.2% of the total population.

Palforzia is a small amount of peanut flour that is given in escalating doses to desensitize a persons allergy and then a maintenance dose is continually administered.  Palforzia has undergone two late stage trials.  The results have been very positive, with about 67% of patients able to to consume 600mg of peanut protein. How much peanut will cause an allergic reaction?

Nearly 80% of those patients were able to tolerate at least 1000mg of peanut protein, and half of those a 2000mg dose.  Aimmune chief believes they will no longer need therapy 3-5 years down the road.

But safety can be an issue. 11% of patients withdrew due to side effects, additionally over the course of treatment 14% of patients receiving Palforzia received epinephrine.  The FDA staff underscored these findings by writing “Palforzia treatment group had an increased number of discontinuations, systemic allergic reactions and eosinophilic esophagitis compared to the placebo treated group.”  There has been some concern in other studies too of higher rates of anaphylaxis of patients who have undergone desensitization.

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety

Aimmune and arch rival DBV Technologies have been locked in a race to market their peanut allergy treatments. Development Program: Viaskin® Peanut

The treatment cost of Palforzia is expected to cost about $4,200/year and Viaskin Peanut at $6,500/year.  An FDA decision for AR101 is expected in January 2020.

Peanut Allergy Cure?

Peanut Desensitization using Xolair

Future Food Allergy Treatment

Update 9/13/2019 Palforzia was voted to be approved by an advisory committee to the FDA (which they usually follow).  They voted 7-2 that it works well, and 8-1 that it is safe. It will carry a black box warning, and will require patients to have an injectable epinephrine and that the initial dose and updosing to be done at a medical office capable of treating anaphlaxis.

 

Filed Under: Blog, Food allergy

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

August 4, 2022

Lentil Allergy, a common allergen on the rise

lentil allergy

July 24, 2022

Viaskin Peanut Patch Safety Results

viaskin peanut patch

July 15, 2022

Flaxseed Allergy, an emerging allergen

flaxseed allergy

July 5, 2022

Itepekimab (Anti IL-33) & Brodalumab (Anti IL-25) for Asthma

Itepekimab and Brodalumab

June 18, 2022

Roflumilast and Tapinarof; Emerging Therapies for Atopic Dermatitis

roflumilast tapinarof

June 9, 2022

Avocado Allergy Comes in Many Flavors

avocado allergy

May 24, 2022

Lirentelimab study for Chronic Urticaria (Hives)

lirentelimab

May 24, 2022

Dupixent for EoE (Eosinophilic Esophagitis); FDA approved and New Dosing

dupixent for eoe

April 30, 2022

What are the best foods for Asthma?

best foods for asthma

April 26, 2022

Best Nasal Polyps Treatment

best nasal polyps treatment

Read More Posts...

Follow Us…

© 2022 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page